Humoral and cellular immunity in patients with hepatic alveolar echinococcosis. A 2 year follow-up with and without flubendazole treatment.
Parameters of humoral and cellular immunity were assessed in 12 patients with alveolar echinococcosis (AE) of the liver before, during and after discontinuation of treatment with flubendazole (FZ). In infected patients, before any medical treatment values of serum IgG, IgA, total haemolytic complement and C4 were significantly higher than those observed in control subjects; IgA levels were higher in jaundiced patients. Specific antibodies assayed by indirect haemagglutination and immunoelectrophoresis were present only in infected patients and were shown to decrease by the sixth month of treatment; however, similar fluctuations were observed without treatment. The percentage and absolute number of B lymphocytes, and total circulating lymphocytes, were significantly lower in patients with AE. An impairment of functional activity of T cells assayed by the leucocyte migration test, with PPD and Candidin as antigens, was demonstrated despite a normal percentage of SRBC rosettes. The 'score' of migration index still decreased during FZ treatment and returned to initial values after the year of follow-up without treatment. These results suggest that human AE is associated with important immunological disturbances. Changes in humoral immunity can be unequivocally considered to be a consequence of the parasite infection. The primary or secondary nature of the impairment of cellular immune responses and its mechanisms remain to be elucidated. Flubendazole could be responsible for an increase of cellular immune alterations in these patients.
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation; D000969:Antinematodal Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003181:Complement C4 / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis; D004444:Echinococcosis, Hepatic / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006386:Hemagglutination Tests; D006801:Humans; D007111:Immunity, Cellular; D007122:Immunoelectrophoresis; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008463:Mebendazole / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008875:Middle Aged
D000906:Antibodies; D000969:Antinematodal Agents; D001562:Benzimidazoles; D003181:Complement C4; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D008463:Mebendazole; D003165:Complement System Proteins; C018945:flubendazole